Duff & Phelps Investment Management Co. Trims Stake in Fresenius Medical Care AG & Co. (NYSE:FMS)

Duff & Phelps Investment Management Co. reduced its holdings in shares of Fresenius Medical Care AG & Co. (NYSE:FMS) by 61.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,141 shares of the company’s stock after selling 55,571 shares during the period. Duff & Phelps Investment Management Co.’s holdings in Fresenius Medical Care AG & Co. were worth $1,380,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Renaissance Group LLC boosted its position in shares of Fresenius Medical Care AG & Co. by 33.3% in the first quarter. Renaissance Group LLC now owns 377,246 shares of the company’s stock worth $15,290,000 after purchasing an additional 94,236 shares during the period. Eqis Capital Management Inc. boosted its position in shares of Fresenius Medical Care AG & Co. by 14.1% in the first quarter. Eqis Capital Management Inc. now owns 9,237 shares of the company’s stock worth $374,000 after purchasing an additional 1,139 shares during the period. Marshall Wace LLP boosted its position in shares of Fresenius Medical Care AG & Co. by 58.5% in the first quarter. Marshall Wace LLP now owns 159,642 shares of the company’s stock worth $6,470,000 after purchasing an additional 58,904 shares during the period. Hardman Johnston Global Advisors LLC boosted its position in shares of Fresenius Medical Care AG & Co. by 2.3% in the first quarter. Hardman Johnston Global Advisors LLC now owns 55,390 shares of the company’s stock worth $2,245,000 after purchasing an additional 1,250 shares during the period. Finally, Citigroup Inc. boosted its position in shares of Fresenius Medical Care AG & Co. by 773.8% in the first quarter. Citigroup Inc. now owns 59,811 shares of the company’s stock worth $2,425,000 after purchasing an additional 52,966 shares during the period. Institutional investors and hedge funds own 1.44% of the company’s stock.

Shares of NYSE:FMS traded up $0.61 during midday trading on Friday, reaching $33.13. 529,800 shares of the company were exchanged, compared to its average volume of 237,109. The company has a current ratio of 0.99, a quick ratio of 0.76 and a debt-to-equity ratio of 0.77. The business’s fifty day moving average is $36.99 and its two-hundred day moving average is $38.62. Fresenius Medical Care AG & Co. has a one year low of $30.99 and a one year high of $53.40. The stock has a market cap of $20.08 billion, a PE ratio of 14.59, a price-to-earnings-growth ratio of 2.40 and a beta of 1.44.

A number of equities analysts have weighed in on FMS shares. Royal Bank of Canada reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Thursday, June 6th. DZ Bank reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Tuesday, July 30th. Zacks Investment Research lowered shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating and set a $41.00 price target for the company. in a research report on Monday, July 1st. BTIG Research lowered shares of Fresenius Medical Care AG & Co. from a “buy” rating to a “neutral” rating in a research report on Thursday, August 1st. Finally, Barclays upgraded shares of Fresenius Medical Care AG & Co. from an “equal weight” rating to an “overweight” rating and set a $40.23 price target for the company in a research report on Thursday, June 20th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $53.05.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Story: Holder of Record

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG & Co. (NYSE:FMS).

Institutional Ownership by Quarter for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.